Issi Rozen, chief business officer at the Broad Institute, is responsible for partnering with the life sciences industry and venture investors and developing innovative scientific and business collaborations. He is also responsible for initiating and establishing new ventures around novel research projects and for licensing the institute’s intellectual property portfolio. Before joining the Broad Institute in 2011, Rozen headed corporate development at Resolvyx Pharmaceuticals, a venture-backed biotech start-up, where he led the business development and partnering efforts. Prior to that, he led the business analysis group at EMD Serono, where he was responsible for evaluating in-licensing and M&A opportunities as well as commercial analytics and forecasting. He is also a co-founder of a number of Boston-based biotech start-ups and is an accomplished jazz guitarist. He earned his M.B.A. at MIT’s Sloan School of Management.